ITHACA, N.Y.--(BUSINESS WIRE)--Rheonix, Inc. today announced positive results from three separate studies of the Rheonix CARD™ (Chemistry And Reagent Device) system presented in poster sessions at the American Association for Clinical Chemistry (AACC) Annual Meeting held in Anaheim, CA, July 25-29, 2010. The data presented demonstrate the utility of the Rheonix CARD™ system as a powerful, analytic platform for the life science industry. In studies conducted by the Company, fully automated custom Rheonix CARD systems were successfully designed for three molecular diagnostic applications. In each case, the Rheonix CARD system’s capacity to achieve highly reliable results was validated using comparator tests, control samples and/or DNA sequencing.
